Multi-center, Double-blind, Randomized, Placebo-controlled, Active-reference, Parallel-group, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs ACT 541468 (Primary) ; Zolpidem
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 30 Jun 2017 Status changed from active, no longer recruiting to completed.
- 09 Jun 2017 Planned End Date changed from 11 Jun 2017 to 16 Jun 2017.
- 19 Apr 2017 Status changed from recruiting to active, no longer recruiting.